Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma.
about
Nutrient-sensitive mitochondrial NAD+ levels dictate cell survivalRedox control of glutamine utilization in cancerRegulation of cell survival and death by pyridine nucleotidesNicotinamide phosphoribosyl transferase (Nampt) is a target of microRNA-26b in colorectal cancer cellsMetabolomics analysis of metabolic effects of nicotinamide phosphoribosyltransferase (NAMPT) inhibition on human cancer cellsThe NADH oxidase ENOX1, a critical mediator of endothelial cell radiosensitization, is crucial for vascular development.Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NADIs PBEF/visfatin/Nampt an authentic adipokine relevant to the metabolic syndrome?Resveratrol differentially regulates NAMPT and SIRT1 in Hepatocarcinoma cells and primary human hepatocytes.Nicotinamide Phosphoribosyltransferase in Human Diseases.Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cellsNampt/PBEF/Visfatin: a regulator of mammalian health and longevity?Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.Nampt: linking NAD biology, metabolism and cancer.Dysregulated pH in Tumor Microenvironment Checkmates Cancer Therapy.EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.
P2860
Q24612868-58D6AF53-8EED-4AD7-94BD-B6647B3F8423Q27005615-56EF0D99-D19A-4F92-A0D8-81D479EBD660Q27026075-41946E76-AAA9-41F7-93E7-D469384E97ECQ28534961-799EA4D0-5C54-4BAE-A707-EA2BD557B147Q28542558-FFEF7D16-76AC-44FD-99AC-C9759455D131Q30573744-0549124B-D570-4E6B-963C-342BE2E81C93Q33336612-4552D537-FDDD-431B-8A39-C3BC3B4E66A7Q34993305-37A9B2B8-AEBC-4567-9CD6-5EE6BF796FC6Q35112888-D881DDDF-3770-4F4E-8517-C893FA0968BBQ35581515-E2E5F007-6770-41F4-AB15-55F50C484E86Q35860727-34146BBE-E2F7-4AC0-BEE3-FAF76CA9041FQ36379543-8E6FD236-6550-4BC2-A0AA-35668726A338Q36536935-F163EFF9-B11C-4ADB-B8BA-96B5DDC5E04DQ36579595-3FD3D895-0237-40A2-A010-3981D49000B9Q37334248-CCBEF3DA-B607-4105-83C7-65B503C49F95Q38181145-E7C13C3C-FE10-4FEB-82C2-A9BE2BE995B2Q38405687-D9F38F2D-E006-4798-9BC6-8DADE9565D59Q38759201-843F5DEA-C4D2-4E45-BF9B-1E9515097DF1
P2860
Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Antiangiogenic potency of FK86 ...... n murine renal cell carcinoma.
@en
Antiangiogenic potency of FK86 ...... n murine renal cell carcinoma.
@nl
type
label
Antiangiogenic potency of FK86 ...... n murine renal cell carcinoma.
@en
Antiangiogenic potency of FK86 ...... n murine renal cell carcinoma.
@nl
prefLabel
Antiangiogenic potency of FK86 ...... n murine renal cell carcinoma.
@en
Antiangiogenic potency of FK86 ...... n murine renal cell carcinoma.
@nl
P2093
P1433
P1476
Antiangiogenic potency of FK86 ...... in murine renal cell carcinoma
@en
P2093
Benno Rattel
Joachim Drevs
Norbert Esser
Roland Löser
P304
P407
P577
2003-11-01T00:00:00Z